BRIEF-Infinity Pharma announces new preclinical data for IPI-549
April 18, 2016 at 08:17 AM EDT
* Preclinical data demonstrate that ipi-549 targets immune cells, alters immune-suppressive microenvironment Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)